BNAC RESEARCH OVERVIEW

Since its inception, the Buffalo Neuroimaging Analysis Center (BNAC) has been establishing itself as a world leader in global and regional quantitative brain atrophy research in multiple sclerosis (MS) and other neurodegenerative disorders.

Numerous peer review publications, books and book chapters, and awards reflect this high quality research activity. Since its inception, BNAC research projects have involved international collaboration with a variety of clinicians and scientists pursuing the use of quantitative magnetic resonance imaging (MRI) to study brain disorders. The BNAC has participated in more than $20 million in research grants. Funding sources for the research have included the National Institutes of Health, National Science Foundation, National Multiple Sclerosis Society, Juvenile Diabetes Foundation, The Lawrence D. Jacobs Foundation, Jog for the Jake Foundation, Biogen-Idec Inc., Teva Pharmaceuticals Inc., Teva Neuroscience Inc., Physicians Imaging Centers, Dell Inc., General Electric, and the State University of New York at Buffalo. The BNAC is affiliated with more than a dozen institutions both nationally and internationally.

The BNAC also computes a variety of other conventional and non-conventional quantitative brain MRI measurements: estimates of T2-, T1-, gadolinium-enhancing and confluence lesion volumes, and calculation of global and regional magnetization transfer, diffusion weighted and tensor, magnetic resonance spectroscopy, functional MRI (fMRI), perfusion and atrophy MRI indices. In addition, BNAC has recently expanded its research to cerebrospinal fluid, susceptibility-weigted imaging,  spinal cord and optic nerve imaging.